Hird, Amanda E., et al. “Abiraterone Vs. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: A Microsimulation Model”. Canadian Urological Association Journal, vol. 14, no. 9, Mar. 2020, pp. E418-27, doi:10.5489/cuaj.6234.